iRadimed (IRMD)
(Delayed Data from NSDQ)
$50.41 USD
+1.32 (2.69%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $50.40 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$50.41 USD
+1.32 (2.69%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $50.40 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Centene (CNC) Divests Apixio to Boost Its Core Business
by Zacks Equity Research
Centene (CNC) completes the sale of Apixio to New Mountain Capital in a bid to dispose of non-core assets and grow its core Managed Care business.
Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why
by Zacks Equity Research
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.
iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
IRadimed (IRMD) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 11.11% and 4.84%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Buys Richmond Post-Acute Care Facility
by Zacks Equity Research
Select Medical (SEM) acquires the Vibra Hospital of Richmond to provide enhanced critical illness recovery care across Virginia.
Zacks.com featured highlights include MercadoLibre, iRadimed, Northeast Community Bancorp and AAON
by Zacks Equity Research
MercadoLibre, iRadimed, Northeast Community Bancorp and AAON are part of the Zacks Screen of the Week article.
4 Best Profitable Stocks to Buy Banking on Net Income Ratio
by Tirthankar Chakraborty
MercadoLibre (MELI), iRadimed (IRMD), Northeast Community Bancorp (NECB) and AAON (AAON) have been selected as the top picks with a high net income ratio.
IRadimed (IRMD) Q4 Earnings Top Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 3.23% and 0.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Hologic, Inc. (HOLX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Hologic (HOLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons Growth Investors Will Love iRadimed (IRMD)
by Zacks Equity Research
iRadimed (IRMD) possesses solid growth attributes, which could help it handily outperform the market.
Cigna (CI) Focuses on Enhancing Pharmacy Offerings in 2023
by Zacks Equity Research
Cigna (CI) decides to integrate cost-effective biosimilars within its commercial formularies from next year in a bid to drive pharmacy revenues.
Here is Why Growth Investors Should Buy iRadimed (IRMD) Now
by Zacks Equity Research
iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Zacks Analyst Blog Highlights ShockWave Medical, iRadimed and Tactile Systems Technology
by Zacks Equity Research
ShockWave Medical, iRadimed and Tactile Systems Technology are part of the Zacks top Analyst Blog.
3 Medical Instruments Stocks With Potential to Outperform
by Indrajit Bandyopadhyay
Here we discuss ShockWave Medical (SWAV), iRadimed (IRMD) and Tactile Systems Technology (TCMD), which have the potential to outperform their industry going forward.
IRadimed (IRMD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 20.83% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 56.10% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 12.50% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
After Plunging 27.4% in 4 Weeks, Here's Why the Trend Might Reverse for iRadimed (IRMD)
by Zacks Equity Research
iRadimed (IRMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
iRadimed (IRMD) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
IRadimed (IRMD) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 4.76% and 0.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Indivior PLC (INVVY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Indivior PLC (INVVY) and iRadimed (IRMD) have performed compared to their sector so far this year.
Here's Why Momentum in iRadimed (IRMD) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how iRadimed (IRMD) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Here's Why Momentum in iRadimed (IRMD) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.